Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 5Breast Neoplasms 5Depression 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Anxiety Disorders 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Lung Neoplasms 2Infertility 2Fatigue 2Carcinoma, Squamous Cell 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Urologic Neoplasms 1Stress, Psychological 1Stomach Neoplasms 1Skin Neoplasms 1Sezary Syndrome 1Sexual Dysfunction, Physiological 1Sarcoma, Kaposi 1Sarcoma 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pneumoperitoneum 1Peritoneal Neoplasms 1Periampullary Tumors 1

Interventions

Temozolomide 44Radiotherapy 16Bevacizumab 9Surgical Procedures, Operative 5Carmustine 5pembrolizumab 4Lomustine 4Drug Therapy 4Sunitinib 3Standard of Care 3Radiation 3Procarbazine 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3Chlorotoxin 3Carboplatin 3Blood Specimen Collection 3tislelizumab 2fludarabine 2camrelizumab 2Radiosurgery 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Hyperbaric Oxygenation 2Ethanol 2Cyclophosphamide 2Chemotherapy, Adjuvant 2CT-322 2Bortezomib 2Aminolevulinic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Glioblastoma × Therapeutics × Clear all
NCT04642937 2023-01-27

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

OX2 Therapeutics

Phase 1 Unknown
24 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡